Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah (NASDAQ/EBR: NYXH) disclosed a transparency notification dated March 19, 2026 after Robelga SRL crossed the 3% threshold on December 30, 2025. The combined holding of Robert Taub and related undertakings equals 4,360,800 voting rights (10.14%) of 43,026,460 total voting rights.
The notification lists 4,310,800 voting rights linked to securities and 50,000 equivalent instruments (warrants expiring 08/06/2027 and 14/06/2028). Ownership chain: Robelga SRL 100% owned by BMI Estate; usufruct by Robert Taub; bare ownership by his children.
Nyxoah (Nasdaq: NYXH) reported Q4 2025 net revenue of €5.6M (Q4 gross €6.3M) and full‑year net revenue of €10.0M, up 347% and 122% year‑over‑year respectively. Q4 gross margin was ~64%. Cash, cash equivalents and financial assets were €48.0M at Dec 31, 2025.
The quarter marked the first full quarter of U.S. commercialization: 145 surgeons trained and 57 U.S. accounts activated. Company expects ~25% sequential net revenue growth in Q1 2026 and another ~25% in Q2 2026.
Nyxoah (NASDAQ: NYXH) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, March 16–19, 2026. Olivier Taelman, CEO, will deliver a corporate presentation on March 16, 2026 at 8:40 am ET. A webcast will be available in the Events section of Nyxoah's Investor Relations website.
The company will be available for one-on-one meetings with institutional investors. Nyxoah's investor presentation is accessible on the Shareholder Information section of the Investor Relations page.
Nyxoah (NASDAQ: NYXH) will release its fourth quarter and full year 2025 financial results on March 19, 2026.
Management will hold a conference call and webcast the same day at 10:30pm CET / 4:30pm ET; registration is required for callers and the archived webcast will be available after the call.
Nyxoah (NASDAQ/EBR: NYXH) received a transparency notification dated February 26, 2026, reporting that Robert Taub and related person BMI Estate now hold 4,360,800 voting rights (9.99%) of total voting rights (43,662,403) as of February 20, 2026.
The holding comprises 4,310,800 linked securities and 50,000 warrants exercisable through 2028. Ownership passes via BMI Estate and Robelga SRL with described usufruct and bare ownership arrangements.
Nyxoah (NASDAQ & Euronext: NYXH) reported updated capital and voting-rights figures following new shares issued on 20 February 2026. Share capital is EUR 6,511,048.19. Total securities and voting rights: 43,662,403 ordinary shares.
The company also disclosed 3,416,319 unissued subscription rights (excluding 462,677 issued-but-ungranted rights), 225 convertible bonds (nominal EUR 91,500 each) and a potential 4,117,500 voting rights upon conversion at EUR 5.00 per share.
Nyxoah (NASDAQ: NYXH) signed a Memorandum of Understanding with Sheikh Shakhbout Medical City on February 18, 2026 to expand access to Genio hypoglossal nerve stimulation therapy in the Middle East.
The MoU targets development of a high-volume implant program, a regional training hub for surgeons and sleep physicians, and exploration of clinical research linking OSA management to chronic and metabolic diseases.
Nyxoah (Nasdaq: NYXH) announced an investment to expand its Belgian manufacturing capacity on January 21, 2026. The company signed an agreement with LégiaPark to create a nearly 2,000 square meters facility in Wallonia that includes a scalable, state-of-the-art cleanroom developed with ABN Cleanroom Technology. The expansion is intended to support growing demand in the United States and international markets, strengthen manufacturing readiness, foster local job creation, and, the company said, help improve its gross margin profile.
Nyxoah (NASDAQ: NYXH) reported preliminary unaudited results for Q4 and full-year 2025 and gave Q1 2026 revenue guidance. Q4 2025 gross revenue is ~€6.3M and net revenue ~€5.7M, up ~348% versus Q4 2024. FY2025 gross revenue is ~€11.0M and net revenue ~€10.0M, up ~122% versus FY2024. Deferred revenue related to disposable patches is ~€0.6M in Q4 and ~€1.0M for FY2025. As of Dec 31, 2025 the company trained 145 surgeons, activated 57 U.S. accounts, and held ~€47.9M in cash, cash equivalents and financial assets. Nyxoah expects U.S. net revenue Q1 2026 to grow ~25% sequentially and international revenue to follow seasonal patterns. Results are preliminary and subject to revision ahead of the 2025 Form 20-F filing.
Nyxoah (Nasdaq: NYXH) received a transparency notification from BNP Paribas Asset Management on January 8, 2026, reporting that BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of total voting rights as of December 31, 2025 (denominator: 43,026,460).
The crossing of the 3% threshold follows a merger on December 31, 2025 between BNP Paribas Asset Management Europe SAS and AXA Investment Managers SA; the parent holding chain includes BNP Paribas Asset Management Holding and BNP Paribas SA, with an exemption noted under the Royal Decree on disclosure of major shareholdings.